두경부암 치료 시장 규모, 점유율, 동향 분석 리포트 : 치료 유형별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2025-2033년)

Head And Neck Cancer Therapeutics Market Summary

The global head and neck cancer therapeutics market size was estimated at USD 2.27 billion in 2024 and is projected to reach USD 6.25 billion by 2033, growing at a CAGR of 11.95% from 2025 to 2033. The market is growing due to the rising incidence of head and neck cancers, increasing demand for targeted and immunotherapy-based treatments, and advancements in diagnostic precision.

In June 2025, GORTEC's Phase III REACH trial showed positive results for avelumab plus radiotherapy in head and neck cancer patients ineligible for cisplatin. The trial met its primary endpoint of improved progression-free survival and demonstrated a favorable safety profile across over 500 enrolled patients. Growing awareness among patients and clinicians regarding personalized oncology care is accelerating early diagnosis and multi-line therapy adoption. The shift toward minimally invasive treatment options with reduced toxicity drives clinical preference for novel drug classes. Expansion of clinical trials and faster regulatory approvals are enhancing product availability across key markets.

The growing prevalence of human papillomavirus (HPV)-associated oropharyngeal cancers is emerging as a significant driver in the head and neck cancer therapeutics market. These HPV-related subtypes often respond differently to treatment, prompting a rise in research and tailored drug development. Clinical guidelines increasingly differentiate therapeutic approaches based on HPV status, fueling demand for precision therapies. Pharmaceutical companies are investing in treatment protocols that address viral oncogenesis, expanding the therapeutic landscape. The increasing incidence of HPV-positive cases among younger adults has shifted the disease demographic, creating new market opportunities. Enhanced public awareness and screening for HPV-related malignancies contribute to earlier diagnosis and treatment initiation.

Adopting combination therapy strategies is gaining momentum in the head and neck cancer therapeutics space, offering improved response rates and survival outcomes. Treatment regimens integrating immunotherapy with chemotherapy or targeted agents are being tested in both first-line and refractory settings. For instance, in June 2025, the FDA approved Keytruda for PD-L1-positive head and neck cancer patients, highlighting the growing focus on biomarker-based therapies. The announcement also emphasized the unmet need in PD-L1-negative patients. CEL-SCI's Multikine aims to address this gap by treating patients before standard therapies, regardless of PD-L1 status. Designed to stimulate an early immune response, Multikine represents a novel approach that could broaden treatment access and improve outcomes across diverse patient groups.

Global Head And Neck Cancer Therapeutics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global head and neck cancer therapeutics market report based on therapy type, route of administration, distribution channel, and region:

• Therapy Type Outlook (Revenue, USD Million, 2021 - 2033)
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Injectable
• Oral
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Retail and Specialty Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapy Type
  • 1.2.2. Route of Administration
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Head and Neck Cancer Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Head and Neck Cancer Therapeutics Market: Therapy Type Business Analysis

• 4.1. Therapy Type Market Share, 2024 & 2033
• 4.2. Therapy Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Therapy Type, 2021 to 2033 (USD Million)
• 4.4. Chemotherapy
  • 4.4.1. Chemotherapy Market, 2021 - 2033 (USD Million)
• 4.5. Immunotherapy
  • 4.5.1. Immunotherapy Market, 2021 - 2033 (USD Million)
• 4.6. Targeted Therapy
  • 4.6.1. Targeted Therapy Market, 2021 - 2033 (USD Million)

Chapter 5. Head and Neck Cancer Therapeutics Market: Route of Administration Business Analysis

• 5.1. Route of Administration Market Share, 2024 & 2033
• 5.2. Route of Administration Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
• 5.4. Injectable
  • 5.4.1. Injectable Market, 2021 - 2033 (USD Million)
• 5.5. Oral
  • 5.5.1. Oral Market, 2021 - 2033 (USD Million)

Chapter 6. Head and Neck Cancer Therapeutics Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2033
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
• 6.4. Retail and Specialty Pharmacies
  • 6.4.1. Retail and Specialty Pharmacies Market, 2021 - 2033 (USD Million)
• 6.5. Hospital Pharmacies
  • 6.5.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 7. Head and Neck Cancer Therapeutics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Route of Administration Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Route of Administration Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Route of Administration Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Route of Administration Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. Uk Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Route of Administration Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Route of Administration Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Route of Administration Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Route of Administration Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Route of Administration Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Route of Administration Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Route of Administration Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Route of Administration Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Route of Administration Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Route of Administration Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Route of Administration Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Route of Administration Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Route of Administration Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Route of Administration Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Route of Administration Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Route of Administration Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Route of Administration Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Route of Administration Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Route of Administration Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Eli Lilly and Company
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Therapy Type Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Sanofi
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Therapy Type Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Merck & Co., Inc.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Therapy Type Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Cumberland Pharmaceuticals Inc.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Therapy Type Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Bristol-Myers Squibb Company
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Therapy Type Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. AstraZeneca
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Therapy Type Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Takeda Pharmaceutical Company Limited
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Therapy Type Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Teva Pharmaceutical Industries Ltd.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Therapy Type Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. F. Hoffmann-La Roche Ltd.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Therapy Type Benchmarking
    • 8.5.9.4. Strategic Initiatives